Stay updated on Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T13:57:38.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The webpage has undergone significant changes, including the removal of detailed study information about a Phase II clinical trial for high-risk ocular melanoma, while adding references to melanoma, a specific study identifier (HCRN-MEL17-309), and collaborators involved in the study.
    Difference
    46%
    Check dated 2025-04-16T02:11:18.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-08T23:54:40.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has updated the status of a clinical trial to 'Unknown' and revised the version number from v2.14.2 to v2.14.3. Additionally, the verification date and the name of the verifying entity have been added.
    Difference
    0.9%
    Check dated 2025-04-01T19:08:06.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-03-03T22:20:16.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T09:36:16.000Z thumbnail image

Stay in the know with updates to Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.